JP2006516542A - 血液循環の改善方法 - Google Patents
血液循環の改善方法 Download PDFInfo
- Publication number
- JP2006516542A JP2006516542A JP2004562740A JP2004562740A JP2006516542A JP 2006516542 A JP2006516542 A JP 2006516542A JP 2004562740 A JP2004562740 A JP 2004562740A JP 2004562740 A JP2004562740 A JP 2004562740A JP 2006516542 A JP2006516542 A JP 2006516542A
- Authority
- JP
- Japan
- Prior art keywords
- extract
- use according
- composition
- leaves
- red grape
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000017531 blood circulation Effects 0.000 title abstract description 8
- 239000000203 mixture Substances 0.000 claims abstract description 33
- 241001593968 Vitis palmata Species 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 22
- 210000003141 lower extremity Anatomy 0.000 claims abstract description 13
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000001301 oxygen Substances 0.000 claims abstract description 12
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 12
- 239000006286 aqueous extract Substances 0.000 claims abstract description 8
- 230000002708 enhancing effect Effects 0.000 claims abstract description 4
- 201000002282 venous insufficiency Diseases 0.000 claims description 39
- 201000002816 chronic venous insufficiency Diseases 0.000 claims description 37
- 239000000284 extract Substances 0.000 claims description 33
- 229930003935 flavonoid Natural products 0.000 claims description 10
- 150000002215 flavonoids Chemical class 0.000 claims description 10
- 235000017173 flavonoids Nutrition 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 230000004089 microcirculation Effects 0.000 claims description 9
- 239000002552 dosage form Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 230000001684 chronic effect Effects 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 241000978499 Brunnichia ovata Species 0.000 claims description 3
- 206010020772 Hypertension Diseases 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 230000007704 transition Effects 0.000 claims description 3
- 206010047249 Venous thrombosis Diseases 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 230000028709 inflammatory response Effects 0.000 claims description 2
- 229940038487 grape extract Drugs 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000000902 placebo Substances 0.000 description 21
- 229940068196 placebo Drugs 0.000 description 21
- 238000005259 measurement Methods 0.000 description 13
- 230000000694 effects Effects 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- 210000003423 ankle Anatomy 0.000 description 10
- 241000219095 Vitis Species 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 230000003247 decreasing effect Effects 0.000 description 7
- 210000002683 foot Anatomy 0.000 description 7
- 206010030124 Oedema peripheral Diseases 0.000 description 4
- 235000009392 Vitis Nutrition 0.000 description 4
- 235000009754 Vitis X bourquina Nutrition 0.000 description 4
- 235000012333 Vitis X labruscana Nutrition 0.000 description 4
- 235000014787 Vitis vinifera Nutrition 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000012669 liquid formulation Substances 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 208000005230 Leg Ulcer Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000007941 film coated tablet Substances 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 2
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 229940045809 horse chestnut seed Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002344 surface layer Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- GEVPIWPYWJZSPR-UHFFFAOYSA-N tcpo Chemical compound ClC1=CC(Cl)=CC(Cl)=C1OC(=O)C(=O)OC1=C(Cl)C=C(Cl)C=C1Cl GEVPIWPYWJZSPR-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000001331 thermoregulatory effect Effects 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- OVSQVDMCBVZWGM-IDRAQACASA-N Hirsutrin Natural products O([C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1)C1=C(c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1=O OVSQVDMCBVZWGM-IDRAQACASA-N 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- DUBCCGAQYVUYEU-VFKUPZNOSA-N Miquelianin Natural products O=C(O)[C@@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](OC2=C(c3cc(O)c(O)cc3)Oc3c(c(O)cc(O)c3)C2=O)O1 DUBCCGAQYVUYEU-VFKUPZNOSA-N 0.000 description 1
- 206010048591 Post thrombotic syndrome Diseases 0.000 description 1
- DUBCCGAQYVUYEU-UHFFFAOYSA-N Querciturone Natural products O1C(C(O)=O)C(O)C(O)C(O)C1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O DUBCCGAQYVUYEU-UHFFFAOYSA-N 0.000 description 1
- 240000000353 Ruscus aculeatus Species 0.000 description 1
- 235000003500 Ruscus aculeatus Nutrition 0.000 description 1
- 229910021607 Silver chloride Inorganic materials 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000000558 Varicose Ulcer Diseases 0.000 description 1
- 206010046996 Varicose vein Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000012675 alcoholic extract Substances 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229940061241 butcher's broom preparation Drugs 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 229940097217 cardiac glycoside Drugs 0.000 description 1
- 239000002368 cardiac glycoside Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- HBKPGGUHRZPDIE-UHFFFAOYSA-N ethoxy-methoxy-sulfanylidene-(2,4,5-trichlorophenoxy)-$l^{5}-phosphane Chemical compound CCOP(=S)(OC)OC1=CC(Cl)=C(Cl)C=C1Cl HBKPGGUHRZPDIE-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- LIKBJVNGSGBSGK-UHFFFAOYSA-N iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Fe+3].[Fe+3] LIKBJVNGSGBSGK-UHFFFAOYSA-N 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- OVSQVDMCBVZWGM-QCKGUQPXSA-N isoquercetin Natural products OC[C@@H]1O[C@@H](OC2=C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)c(O)c4)[C@H](O)[C@@H](O)[C@@H]1O OVSQVDMCBVZWGM-QCKGUQPXSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000005592 lipodermatosclerosis Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- DKXULEFCEORBJK-UHFFFAOYSA-N magnesium;octadecanoic acid Chemical compound [Mg].CCCCCCCCCCCCCCCCCC(O)=O DKXULEFCEORBJK-UHFFFAOYSA-N 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- DUBCCGAQYVUYEU-ZUGPOPFOSA-N miquelianin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O DUBCCGAQYVUYEU-ZUGPOPFOSA-N 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 229910000510 noble metal Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 208000030212 nutrition disease Diseases 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- OVSQVDMCBVZWGM-QSOFNFLRSA-N quercetin 3-O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-QSOFNFLRSA-N 0.000 description 1
- LOJXBHNAFUDMIQ-UHFFFAOYSA-N quercetin-3-alpha-glucuronide Natural products OC1OC(C(O)C(O)C1O)C(=O)Oc1c(oc2cc(O)cc(O)c2c1=O)-c1ccc(O)c(O)c1 LOJXBHNAFUDMIQ-UHFFFAOYSA-N 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229930002534 steroid glycoside Natural products 0.000 description 1
- 150000008143 steroidal glycosides Chemical class 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 208000027185 varicose disease Diseases 0.000 description 1
- 208000037997 venous disease Diseases 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- External Artificial Organs (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Distillation Of Fermentation Liquor, Processing Of Alcohols, Vinegar And Beer (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02029107A EP1435242A1 (en) | 2002-12-31 | 2002-12-31 | Method of improvement of blood circulation |
| PCT/EP2003/014147 WO2004058280A1 (en) | 2002-12-31 | 2003-12-12 | Method of improvement of blood circulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006516542A true JP2006516542A (ja) | 2006-07-06 |
| JP2006516542A5 JP2006516542A5 (enExample) | 2007-02-08 |
Family
ID=32479738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004562740A Pending JP2006516542A (ja) | 2002-12-31 | 2003-12-12 | 血液循環の改善方法 |
Country Status (18)
| Country | Link |
|---|---|
| EP (2) | EP1435242A1 (enExample) |
| JP (1) | JP2006516542A (enExample) |
| AT (1) | ATE545426T1 (enExample) |
| AU (1) | AU2003290031A1 (enExample) |
| BR (1) | BR0317895A (enExample) |
| CA (1) | CA2512147C (enExample) |
| CY (1) | CY1112766T1 (enExample) |
| DK (1) | DK1581239T3 (enExample) |
| ES (1) | ES2382461T3 (enExample) |
| MX (1) | MXPA05007095A (enExample) |
| PE (1) | PE20040932A1 (enExample) |
| PL (1) | PL215868B1 (enExample) |
| PT (1) | PT1581239E (enExample) |
| RU (1) | RU2341280C2 (enExample) |
| SI (1) | SI1581239T1 (enExample) |
| TW (1) | TW200501973A (enExample) |
| UA (1) | UA85548C2 (enExample) |
| WO (1) | WO2004058280A1 (enExample) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011512320A (ja) * | 2007-08-31 | 2011-04-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 赤ブドウの葉の抽出物を含む噴霧可能な組成物 |
| EP2322158A2 (en) | 2005-10-26 | 2011-05-18 | Kao Corporation | Resveratrol and/or grape leaf extract for energy metabolism activation |
| KR20170005873A (ko) * | 2014-05-27 | 2017-01-16 | 에스에스 세야쿠 가부시키 가이샤 | 추위 민감증을 포함하는 전신 증상을 개선하기 위한 경구 조성물 |
| WO2020204479A1 (ko) * | 2019-03-29 | 2020-10-08 | 주식회사 유니베라 | 포도잎 추출물 및 병풀 추출물을 포함하는 정맥순환 장애 개선용 조성물 |
| JP2021003478A (ja) * | 2019-06-27 | 2021-01-14 | 廉士 澤田 | 生体センサ |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102008012908A1 (de) * | 2008-03-06 | 2009-09-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Methode zum anti-inflammatorischen und anti-ödematösen Schutz von explantiertem biologischen Material bis zu seiner Transplantation in Patienten |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001028363A1 (en) * | 1999-10-20 | 2001-04-26 | Boehringer Ingelheim International Gmbh | Method for treatment of chronic venous insufficiencies using an extract of red vine leaves |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE617039A (enExample) * | 1961-05-13 | |||
| FR2276059A1 (fr) * | 1974-06-25 | 1976-01-23 | Agronomique Inst Nat Rech | Procede d'extraction de pigments vegetaux de la classe des facteurs vitaminiques p a partir de plantes en contenant |
-
2002
- 2002-12-31 EP EP02029107A patent/EP1435242A1/en not_active Withdrawn
-
2003
- 2003-12-12 DK DK03782385.3T patent/DK1581239T3/da active
- 2003-12-12 ES ES03782385T patent/ES2382461T3/es not_active Expired - Lifetime
- 2003-12-12 BR BR0317895-1A patent/BR0317895A/pt not_active Application Discontinuation
- 2003-12-12 PL PL378344A patent/PL215868B1/pl unknown
- 2003-12-12 UA UAA200507494A patent/UA85548C2/ru unknown
- 2003-12-12 WO PCT/EP2003/014147 patent/WO2004058280A1/en not_active Ceased
- 2003-12-12 AU AU2003290031A patent/AU2003290031A1/en not_active Abandoned
- 2003-12-12 JP JP2004562740A patent/JP2006516542A/ja active Pending
- 2003-12-12 CA CA2512147A patent/CA2512147C/en not_active Expired - Lifetime
- 2003-12-12 RU RU2005124164/15A patent/RU2341280C2/ru active
- 2003-12-12 PT PT03782385T patent/PT1581239E/pt unknown
- 2003-12-12 MX MXPA05007095A patent/MXPA05007095A/es active IP Right Grant
- 2003-12-12 AT AT03782385T patent/ATE545426T1/de active
- 2003-12-12 EP EP03782385A patent/EP1581239B1/en not_active Expired - Lifetime
- 2003-12-12 SI SI200332136T patent/SI1581239T1/sl unknown
- 2003-12-29 TW TW092137312A patent/TW200501973A/zh unknown
-
2004
- 2004-01-05 PE PE2004000018A patent/PE20040932A1/es not_active Application Discontinuation
-
2012
- 2012-05-08 CY CY20121100426T patent/CY1112766T1/el unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001028363A1 (en) * | 1999-10-20 | 2001-04-26 | Boehringer Ingelheim International Gmbh | Method for treatment of chronic venous insufficiencies using an extract of red vine leaves |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2322158A2 (en) | 2005-10-26 | 2011-05-18 | Kao Corporation | Resveratrol and/or grape leaf extract for energy metabolism activation |
| JP2011512320A (ja) * | 2007-08-31 | 2011-04-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 赤ブドウの葉の抽出物を含む噴霧可能な組成物 |
| KR20170005873A (ko) * | 2014-05-27 | 2017-01-16 | 에스에스 세야쿠 가부시키 가이샤 | 추위 민감증을 포함하는 전신 증상을 개선하기 위한 경구 조성물 |
| JP2017529314A (ja) * | 2014-05-27 | 2017-10-05 | エスエス製薬株式会社 | 冷え症等の全身症状改善用経口組成物 |
| US10695392B2 (en) | 2014-05-27 | 2020-06-30 | Ssp Co. Ltd | Oral composition for improving systemic symptoms including sensitivity to cold |
| KR102395338B1 (ko) | 2014-05-27 | 2022-05-10 | 에스에스 세야쿠 가부시키 가이샤 | 추위 민감증을 포함하는 전신 증상을 개선하기 위한 경구 조성물 |
| WO2020204479A1 (ko) * | 2019-03-29 | 2020-10-08 | 주식회사 유니베라 | 포도잎 추출물 및 병풀 추출물을 포함하는 정맥순환 장애 개선용 조성물 |
| JP2021003478A (ja) * | 2019-06-27 | 2021-01-14 | 廉士 澤田 | 生体センサ |
| JP7262079B2 (ja) | 2019-06-27 | 2023-04-21 | 廉士 澤田 | 生体センサ |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1581239B1 (en) | 2012-02-15 |
| CA2512147A1 (en) | 2004-07-15 |
| CY1112766T1 (el) | 2016-02-10 |
| DK1581239T3 (da) | 2012-06-11 |
| UA85548C2 (ru) | 2009-02-10 |
| EP1581239A1 (en) | 2005-10-05 |
| TW200501973A (en) | 2005-01-16 |
| PE20040932A1 (es) | 2004-12-31 |
| ATE545426T1 (de) | 2012-03-15 |
| BR0317895A (pt) | 2005-12-06 |
| CA2512147C (en) | 2014-09-16 |
| MXPA05007095A (es) | 2005-09-12 |
| RU2005124164A (ru) | 2006-03-20 |
| ES2382461T3 (es) | 2012-06-08 |
| PT1581239E (pt) | 2012-05-11 |
| PL378344A1 (pl) | 2006-03-20 |
| WO2004058280A1 (en) | 2004-07-15 |
| RU2341280C2 (ru) | 2008-12-20 |
| PL215868B1 (pl) | 2014-02-28 |
| SI1581239T1 (sl) | 2012-06-29 |
| EP1435242A1 (en) | 2004-07-07 |
| AU2003290031A1 (en) | 2004-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1197481C (zh) | 用红藤叶萃取物治疗慢性静脉机能不全的方法 | |
| KR101189108B1 (ko) | 황칠나무 추출물을 포함하는 남성 성기능 개선용 조성물 | |
| Greyling et al. | Effects of wine and grape polyphenols on blood pressure, endothelial function and sympathetic nervous system activity in treated hypertensive subjects | |
| US20060198913A1 (en) | Method of improvement of blood circulation | |
| JP2006516542A (ja) | 血液循環の改善方法 | |
| JP4989071B2 (ja) | 赤ブドウ葉抽出物を含むフィルムコート錠 | |
| US20040151769A1 (en) | Film coated tablet containing an extract of red vine leaves | |
| KR20010018271A (ko) | 심혈관 질환 치료제의 조성 및 그의 제조방법 | |
| Febriza et al. | Effectiveness of consuming celery leaf decoction (Apium graveolens) in reducing cholesterol levels, blood pressure, and mean arterial blood pressure (MAP) | |
| KR100850503B1 (ko) | 복합 생약 추출물을 유효성분으로 함유하는 성기능 개선용조성물 | |
| JP2016079124A (ja) | むくみ抑制または改善剤 | |
| CN107661422B (zh) | 一种防治冠心病的中药组合物及其制备方法 | |
| TW202535446A (zh) | Ｔｉｅ２活化劑、血管成熟劑或血管穩定劑及其飲食品，以及毛細血管改善劑、毛細血管改善用飲食品 | |
| KR20180075136A (ko) | 비스코톡신과 미슬토 폴리사카라이드를 주성분으로 함유하는 코골이 수면 무호흡증의 치료 및 완화용 조성물 | |
| ZA200505059B (en) | Film coated tablet comprising an extract of red vine leaves | |
| TWI477280B (zh) | 治療、改善女性生理期與經期症候群的巧克力草本中藥複方組合物 | |
| Braun | Pine-bark Extract: Pinus Maritime | |
| HK1089942A (en) | Film coated tablet comprising an extract of red vine leaves |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061212 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20061212 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100524 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100824 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100831 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101102 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20101129 |